Company Overview and News


Add CLRBW
to your dashboard

Headline News

Cellectar Biosciences' (CLRB) CEO Jim Caruso on Q3 2017 Results - Earnings Call Transcript

2017-11-10 seekingalpha
Good day, ladies and gentlemen and welcome to the Cellectar Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. (43-0)

Rubius Poaches New CMO From GlaxoSmithKline

2017-09-27 biospace
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Rubius Therapeutics, a “Fierce 15” company pioneering the creation of a new class of extraordinarily active, ready-to-use and life-changing cellular therapies, today announced the appointment of Chris Carpenter, M.D., Ph.D., as chief medical officer. Dr. Carpenter will oversee Rubius’ clinical and regulatory strategy as the Company prepares to enter human clinical trials in 2018. (17-0)

BRIEF-Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics

2017-09-21 reuters
* Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics to develop new phospholipid drug conjugates (43-0)

Cellectar Biosciences' (CLRB) CEO Jim Caruso on Q2 2017 Results - Earnings Call Transcript

2017-08-15 seekingalpha
Good day, ladies and gentlemen and welcome to the Cellectar Second Quarter Earnings Conference Call. At this time, all participants are in listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions]

3 Things In Biotech You Should Learn Today: August 10, 2017

2017-08-10 seekingalpha
Welcome to new edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep up with the recent news in the biotech and pharmaceutical industries. (0-1)

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Cellectar Biosciences, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

2017-06-15 prnewswire
NEW YORK, June 15, 2017 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Cellectar Biosciences, Inc. (NASDAQ: CLRB).

Cellectar Biosciences' (CLRB) CEO Jim Caruso on Q1 2017 Results - Earnings Call Transcript

2017-05-12 seekingalpha
Good day, ladies and gentlemen and welcome to the Cellectar First Quarter 2017 Financial and Corporate Performance Conference Call. At this time, all participants are in listen-only mode. [Operator Instructions] As a reminder, this conference maybe recorded. It’s now my pleasure to hand the conference over to Mr. Jules Abraham from JQA Partners. Sir, please proceed.

Cellectar Biosciences' (CLRB) CEO James Caruso on Q4 2016 Results - Earnings Call Transcript

2017-03-16 seekingalpha
Good day, ladies and gentlemen and welcome to the Cellectar Biosciences Fourth Quarter Earnings Conference Call. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions]

Cellectar Biosciences to Present at the 2nd Annual Disruptive Growth & Healthcare Conference

2017-02-09 accesswire
NEW YORK, NY / ACCESSWIRE / February 9, 2017 / Cellectar Biosciences (NASDAQ: CLRB), an oncology-focused, clinical stage biotechnology company, announces today that it will be presenting at the 2nd Annual Disruptive Growth & Healthcare Conference on Thursday, February 16 at 8:30 AM EST in the Tribeca Room of Convene Conference Center, 730 Third Avenue in New York City.

Cellectar nabs new patent covering lead product candidate CLR 131; shares ahead 23%

2017-01-25 seekingalpha
Nano cap Cellectar Biosciences (CLRB +22.5%) heads north on a healthy 20x surge in volume in response to its announcement that the U.S. Patent and Trademark Office has issued a new patent (No. 9,550,002) covering method of use for lead product candidate CLR 131, in addition to CLR 125, for the treatment of cancer.

PCG Advisory Group (PCG) Announces Clients Participating During the 9th Annual Biotech Showcase(TM) Event and the 35th Annual J.P. Morgan Healthcare Conference in San Francisco

2016-12-22 accesswire
NEW YORK, NY / ACCESSWIRE / December 22, 2016 / PCG Advisory Group, a New York based leading investor and public relations firm, announces clients that will be participating in industry events around the upcoming J.P. Morgan Healthcare Conference and 9th Annual Biotech Showcase Event, which are taking place in San Francisco, January 9-11, 2017.

Cellectar Biosciences announces USPTO grants patent allowances for radiotherapeutic PDCs for variety of solid tumor types

2016-12-15 seekingalpha
Cellectar Biosciences (NASDAQ:CLRB) announces that the United States Patent and Trademark Office (USPTO) has issued patent allowances covering method of use for radiotherapy with the company’s lead compound, CLR 131, as well as CLR 125, another of the company’s pipeline products using its proprietary phospholipid drug conjugate to deliver a radiotherapeutic.

BRIEF-Celsion Corp announces positive DSMB review of Phase 1B ovation study in ovarian cancer

2016-12-01 feeds.reuters
* Celsion - study to continue as planned, co to proceed with completing dosing in fourth and final patient cohort, which is currently enrolling patients.

CUSIP: 15117F120